1. Home
  2. NTZ vs CVM Comparison

NTZ vs CVM Comparison

Compare NTZ & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natuzzi S.p.A.

NTZ

Natuzzi S.p.A.

HOLD

Current Price

$3.05

Market Cap

34.3M

ML Signal

HOLD

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$3.50

Market Cap

32.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTZ
CVM
Founded
1959
1983
Country
Italy
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.3M
32.4M
IPO Year
1998
1996

Fundamental Metrics

Financial Performance
Metric
NTZ
CVM
Price
$3.05
$3.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
38.3K
Earning Date
04-13-2023
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.45
52 Week Low
$2.15
$0.18
52 Week High
$5.50
$13.48

Technical Indicators

Market Signals
Indicator
NTZ
CVM
Relative Strength Index (RSI) 41.80 35.57
Support Level $2.66 $3.40
Resistance Level $3.20 $6.75
Average True Range (ATR) 0.28 0.30
MACD -0.03 0.02
Stochastic Oscillator 19.39 20.65

Price Performance

Historical Comparison
NTZ
CVM

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: